<a href="https://www.fiercebiotech.com/biotech/amgen-abandons-candidates-cancer-and-sjogrens-syndrome-after-ph-2-data-not-par" hreflang="en">Amgen abandons candidates for cancer, Sjögren’s syndrome over weak ph. 2 data</a>
Amgen has discontinued midstage drug candidates for cancer and Sjögren’s syndrome due to poor phase 2 trial results, terminating five clinical trials. Despite this setback, the company continues to pursue treatment options for Sjögren’s with a different candidate, dazodalibep, currently in phase 3 trials.
Amgen's strategic decision to discontinue multiple drug candidates due to insufficient phase 2 data highlights the critical importance of robust efficacy in early clinical trials for continued investment in drug development. This underscores the potential opportunity for healthtech and biotech professionals to innovate in trial design or predictive analytics to better assess candidate viability early on, thereby reducing costly late-stage failures.